Abstract: Pharmaceutical compositions and dosage forms comprising an adsorbent, and an adverse agent, such as an opioid antagonist. In one embodiment, at least a portion of the adverse agent is on the surface or within the micropore structure of an adsorbent material. The pharmaceutical compositions and dosage forms comprising the adsorbent and the adverse agent are useful for preventing or discouraging tampering, abuse, misuse or diversion of a dosage form containing an active pharmaceutical agent, such as an opioid. The present invention also relates to methods for treating a patient with such a dosage form, as well as kits containing such a dosage form with instructions for using the dosage form to treat a patient. The present invention further relates to process for preparing such pharmaceutical compositions and dosage forms.

Abstract: Methods of managing and treating a keloid in mammal are disclosed. An embodiment includes managing and treating a keloid by covering the keloid with flurandrenolide tape, applying graphites ointment on the keloid and applying witch hazel ointment on the keloid. A further embodiment includes covering the keloid with flurandrenolide tape; and removing the flurandrenolide tape from the keloid after 5 to 10 hours; and applying witch hazel ointment on the keloid; and applying capsaicin ointment on the keloid. Yet another embodiment comprises steps of making and providing a mixture including equal proportions by mass (or weight) of flurandrenolide, witch hazel, graphites and capsaicin; and applying the mixture on the keloid in a manner that includes covering the keloid with the mixture.

Abstract: The present disclosure relates to capsules having a core and one or more capsular walls surrounding the core, wherein at least one of the capsular walls comprises a polymer comprising epsilon-poly-lysine or a derivative thereof.

Abstract: The present invention relates to cosmetic make-up compositions, in particular mascaras, comprising carbon black encapsulated in a spherical silica matrix. These compositions are characterized by a deep and glossy black colour.

Abstract: The present invention is a solution or colloid of fullerene, SWNTs, or graphene in cyclic terpenes, lactones, terpene-alcohol, fatty-acid alcohols, and lactones following ultrasonication and ultracentrifugation processing, for oil-energy, biological, electrical-thermal applications. The compositions are useful as fuel/oil/grease/gels (synthetic included), oil/fuel/additives/propellants, identification dyes, and heat-transfer fluids. Other functions are phase-change fluids for solar energy power plants, antifreeze, electronic dyes, electrolytic fluid/solvent, electrically-thermally conductive material for electrochemical, dielectric, filler/adhesive for semiconductor, eletro-optical, and liquid crystal substrates/coatings for touch sensitive transmissive or reflective displays. When combined with gelatin the formulations can function as dichroic-optical coatings for thin-films/waveguides/holograms.

Abstract: A method of inducing mineralization in a bone cell is described. The method comprises contacting a bone cell with a composition comprising nanoparticles. The nanoparticles can be single-walled carbon nanotubes, hydroxyapatite nanoparticles, TiO2 nanoparticles or silver nanoparticles. The bone cell can be an osteoblast cell. A method for increasing bone mass, bone healing or bone formation is also described which comprises administering to a subject in need thereof an effective amount of a composition comprising nanoparticles. The subject can suffer from a bone disease such as osteoporosis. The subject can suffer from a bone fracture and the method can comprise contacting bone cells near the bone fracture site with the composition. The composition can further comprise a pharmaceutically acceptable carrier.

Abstract: An adsorbent for an oral administration, comprising a surface-modified spherical activated carbon wherein an average particle diameter is 50 to 200 ?m, a specific surface area determined by a BET method is 700 m2/g or more, a bulk density is less than 0.54 g/mL, a total amount of acidic groups is 0.30 to 1.20 meq/g, and a total amount of basic groups is 0.20 to 0.9 meq/g is disclosed. The adsorbent for an oral administration has a high adsorbability, and is capable of adsorbing a large amount of toxins during a retention period in an intestine, and of remarkably reducing an amount of urinary proteins excretion.

Abstract: A method of mitigating or eliminating the odor associated with the feces or flatulence of an animate subject, whether human or animal, by means of administering activated carbon, whether alone or in composition with further inert ingredients, to the subject for ingestion and digestion of the same in advance of the subject either defecating or expelling flatulence.

Abstract: A pharmaceutical composition for treating urinary system disorders includes a carbon material carried by a water-containing carrier and having a carbon content over 60 percentage by weight (wt %), such that both of the carbon material and the water-containing carrier constitute a pharmaceutically acceptable water-containing carrier carrying the carbon material, and the carbon material falls within a range of 0.1 mg/ml to 500 mg/ml per unit dose and has a diameter from 2 nm to 2 mm, such that the pharmaceutical composition is capable of reducing symptoms of cystitis by contacting the carbon material with a bladder or related tissues of the bladder in an animal body.

Abstract: The present invention relates to a medical device comprising both pyrolytic carbon and an NO generator, methods of making same, and methods of using same.

Abstract: A black colouring substance, comprising carbo vegetabilis as a black pigment. The colouring substance may be used as a colouring agent in the manufacture of e.g. food and pharmaceutical products.

Abstract: Compositions which deliver adsorbents, alone or in combination with active drug “degrading molecules,” in a site-specific manner to the intestine, and which eliminate or at least lower the concentration of residual unwanted material within the intestine, and methods of treatment using the compositions, are disclosed. The compositions are ideally designed to specifically release the adsorbents in a programmed manner at a specific site of the intestinal tract. Programmed delivery prevents adsorbents from interfering with the normal absorption process of a given molecule after oral absorption, until it reaches the lower part of the small intestine. The compositions can be used to adsorb, and therefore remove, any residual drug, metabolite thereof, or bacterial toxin after oral or parenteral administration which would otherwise cause adverse effects in the lower intestine and/or colon.

Abstract: A method for differentiating mesenchymal stem cells (MSCs) towards osteoblasts and other connective tissue using nanoparticles and electromagnetic stimulation Osteoinductive materials produced using said method may be useful for bone regeneration and reconstruction in treatment of bone trauma and bone related diseases, and to correct birth defects.

Abstract: A bio compatible free radical suspension, comprising of oxygen and electronically modified reaction intermediates, where a fluorocarbon is used as an inert medium for stabilization of reaction intermediates. A stabilized bio compatible electronically modified derivative suspension is produced by the subjecting a fluorocarbon to certain stressors, such as oxidizing agents, reactive intermediates, physiological gases, benzo-?-pyrone derivatives, ultrasonic-cavitation, electric fields, magnetic fields, UV radiation, active metal catalyst, surfactant reactants, buffers, electrolytes, glucose, glucose derivatives, for the purpose of inducing a cascading immune response.

Abstract: A method to effectively treat the adverse events of ingested orlistat, and to maintain the effectiveness of ingested orlistat, the method comprising the steps of: ingesting a compound of orlistat to irreversibly bind with lipase enzymes of the gastrointestinal tract; ingesting a compound of simethicone to cause undigested fats to remain in an emulsified state in the bowel; and ingesting an enteric coated activated charcoal member to absorb emulsified fats only in the lower bowel, thus preventing the adverse events associated with the ingestion of orlistat alone.

Abstract: Nanosilver porous material particles and method for manufacturing the same are disclosed. The nanosilver porous material particles include nanosilver particles distributed on the surface thereof. First, a nanosilver precursor is dissolved in water and a proper quantity of a fixation agent is added to form a solution. Next, a proper quantity of the porous material particles is added into the solution and that is mixed well to form a suspension. Next, the suspension is allowed to stand for a predetermined period of time, and then the suspension is filtered to separate the porous material particles from the solution. Finally, the resulting porous material particles are baked and dried.

Abstract: Adsorbent carbon microspheres are administered to treat irritable bowel syndrome or symptoms associated with irritable bowel syndrome.

Abstract: The current application relates to a method for solubilizing (dispersing and debundling) of carbon nanotubes using a gemini surfactant, which has head groups and a spacer linking the head groups. The dispersion of nanotubes produced by said method can be used as a delivery system for biologically active agents to an organism.

Abstract: Compositions which deliver adsorbents, alone or in combination with active drug “degrading molecules,” in a site-specific manner to the intestine, and which eliminate or at least lower the concentration of residual unwanted material within the intestine, are disclosed. Methods of treatment using the compositions are also disclosed. The material to be eliminated can include residual active antibiotics, metabolites, bacterial or other toxins, and drugs which cause side effects in the gastrointestinal tract. The adsorbents can be formulated in capsules, tablets or any acceptable pharmaceutical composition, and are ideally designed to specifically release the adsorbents in a programmed manner at a specific site of the intestinal tract. The programmed delivery prevents adsorbents from interfering with the normal absorption process of a given molecule after oral absorption, until it reaches the lower part of the small intestine.

Abstract: The invention relates to an edible product containing a decontaminant. Particularly, the invention relates to an edible product, for instance, a food-like product, containing an effective amount of activated charcoal to mitigate, substantially reduce or cause the cessation of at least one adverse effect associated with the ingestion of a toxic substance. The invention also relates to methods for manufacturing such a decontaminant edible product and uses thereof.

Abstract: The invention relates to a method for treating an overdosing with active substance dabigatran etexilate of formula I optionally in the form of the pharmaceutically acceptable salts thereof, comprising the administration of an effective amount of charcoal.

Abstract: The invention relates to a substance mixture on the basis of a mixture of essential oils, wherein the oil mixture contains juniper oil and turpentine oil, in particular turpentine oil of the duster pine type or substantially comprises them, and wherein the substance mixture preferably furthermore contains a liquid and/or dissolved active ingredient or a mixture of a plurality thereof and/or an active ingredient in powder form or a mixture of a plurality thereof.

Abstract: Non-activated charcoals from living plant materials are useful as ion exchange agents for adsorbing cations from an environment, especially metal ions.

Abstract: Compositions and methods are disclosed for imparting super-hydrophobic properties to cosmetics, in particular mascaras. The compositions comprise a hydrophobic film former in combination with hydrophobically-modified iron oxide pigments and/or carbon black.

Abstract: The present invention provides methods for retaining and expressing physiologically active substances in a target tissue-specific-manner, by administering the physiologically active substances to target submucous tissue. Specifically, the present inventors demonstrated that, when physiologically active substances were directly administered into submucous tissues without using a carrier, the physiologically active substances were effectively and safely retained at the administration sites over long periods without loss and diffusion, and produced the effect acting in a reservoir-like fashion. The physiologically active substances administered as described above were demonstrated to produce the therapeutic effect without having an influence on organs other than the administered organ.

Abstract: The invention relates to an edible product containing a decontaminant. Particularly, the invention relates to an edible product, for instance, a food-like product, containing an effective amount of activated charcoal to mitigate, substantially reduce or cause the cessation of at least one adverse effect associated with the ingestion of a toxic substance. The invention also relates to methods for manufacturing such a decontaminant edible product and uses thereof.

Abstract: Adsorbent carbon microspheres are administered to treat irritable bowel syndrome or symptoms associated with irritable bowel syndrome.

Abstract: A method for producing bronchorelaxation in a human or an animal affected by airway obstruction comprises administration of a pharmacologically effective amount of elemental iodine on activated charcoal (iodinated activated charcoal) to the intestine of said human or animal. A pharmaceutical composition comprising elemental iodine on activated charcoal and uses thereof is also disclosed.

Abstract: A method includes positioning an effective amount of a thermal target material at a treatment site of a patient. The treatment site, that is, the location of the thermal target material, comprises a location adjacent to biological tissue to be treated. The thermal target material includes carbon molecules preferably in a carrier fluid. Regardless of the particular structure of the carbon, the carbon molecules in the material heat very rapidly in response to incident microwave radiation and radiate heat energy. The heat energy radiated from an effective amount of the thermal target material when subjected to an effective quantity of microwave energy causes localized heating around the thermal target material. This localized heating may be applied for therapeutic purposes. However, the microwave radiation necessary to produce therapeutically effective heating is insufficient to cause cellular damage in the biological tissue by direct absorption in the tissue.

Abstract: A method to effectively treat the adverse events of ingested orlistat, and to maintain the effectiveness of ingested orlistat, the method comprising the steps of: ingesting a compound of orlistat to irreversibly bind with lipase enzymes of the gastrointestinal tract; ingesting a compound of simethicone to cause undigested fats to remain in an emulsified state in the bowel; and ingesting an enteric coated activated charcoal member to absorb emulsified fats only in the lower bowel, thus preventing the adverse events associated with the ingestion of orlistat alone.

Abstract: Adsorbent carbon microspheres are administered to treat irritable bowel syndrome or symptoms associated with irritable bowel syndrome.

Abstract: An adsorbent for oral administration, characterized by comprising a spherical activated carbon, wherein a diameter is 0.01 to 1 mm, a specific surface area determined by Langmuir's adsorption equation is 1000 m2/g or more, and a diffraction intensity ratio, an R value, determined by an equation (1): R=(I15?I35)/(I24?I35)??(1) wherein I15 is a diffraction intensity when a diffraction angle (2?) of an X-ray diffractometry is 15°, I35 is a diffraction intensity when a diffraction angle (2?) of an X-ray diffractometry is 35°, and I24 is a diffraction intensity when a diffraction angle (2?) of an X-ray diffractometry is 24°, is 1.4 or more; and an adsorbent for an oral administration, characterized by comprising a surface-modified spherical activated carbon, wherein a diameter is 0.01 to 1 mm, a specific surface area determined by Langmuir's adsorption equation is 1000 m2/g or more, a total amount of acidic groups is 0.40 to 1.00 meq/g, a total amount of basic groups is 0.40 to 1.

Abstract: A medical adsorbent which produces minimal side-effects such as constipation, has excellent adsorption for ionic organic compounds such as causative substances of uremia, exhibits adequate adsorption performance at low doses and avoids adsorption of high-molecular compounds necessary for the body, such as enzymes and polysaccharides. The medical adsorbent comprises activated carbon obtained by carbonizing a spherical phenol resin in a nitrogen atmosphere at a temperature of 400-1000° C., activating the carbonized spherical phenol resin at a temperature of 800-1000° C., washing it with dilute hydrochloric acid, heat treating it at a temperature of 150-1000° C. in a mixed gas comprising oxygen and nitrogen and then sorting it; the activated carbon has an area to weight ratio of 500-2000 m2/g, a pore volume of 0.2-1.0 mL/g and a packing density of 0.5-0.75 g/mL.

Abstract: When C60 was added to synovial fibroblasts, infiltrating lymphocytes, and macrophages, and the inflammatory cytokine production level was measured, the inflammatory cytokine production level was significantly suppressed in all cells. Furthermore, when C60 was added to osteoclast precursor cells and cultured in the presence of osteoclast differentiation-inducing factors, a certain concentration or more of C60 suppressed their differentiation into osteoclasts. Observation of the effect of C60 addition on bone resorption showed that C60 suppressed bone resorption by osteoclasts. In addition, the use of arthritis model animals confirmed in vivo that C60 suppressed inflammatory symptoms, as well as bone resorption and bone destruction by osteoclasts. C60 is effective for treating arthritic diseases such as rheumatoid arthritis through its effects of suppressing osteoclast differentiation, bone resorption, and inflammatory cytokines.

Abstract: A medicament to decrease the adverse events of Olistat, an oral lipase inhibitor, arranged in combination with Olistat, comprising: an emulsifier, a bowel relaxant and one or more chelating agents to absorb and mechanically agitate non-digested fats.

Abstract: A composition to treat wounds comprising non-geniculate marine coral algae in combination with one or more sugars.

Abstract: Orally administrable, site-specific (colonic), particulate delivery systems including adsorbents are disclosed. When delivered specifically to the colon, they can remove various substances present in, or as they reach, the colon. Methods of treatment using the delivery systems, and methods of preparing the delivery systems, are also disclosed. The particulate delivery systems are based on adsorbent matrices encapsulated into and/or onto particles, which selectively deliver the adsorbents to the colon. Representative drug delivery devices include pectin beads, which can optionally be crosslinked with metal ions such as zinc and/or calcium. The delivery system protects the adsorbent and prevents its adsorbing effect in the upper gastro-intestinal (GI) tract. When the particles are made from pectin, and the beads are administered to the colon, specific pectinolytic enzymes in the colon degrade the pectin, allowing the adsorbent to be released and to be fully active.

Abstract: The invention relates to the use of charcoal in the manufacture of an oral composition for the treatment of an inflammatory condition other than an inflammatory bowel disease and other than interstitial or other inflammation within the kidney.

Abstract: A composition including a base and a plurality of abrasive particles. An apparatus including a head, and an applicator coupled to the head, the applicator having dimensions suitable for contacting localized areas of human skin. A method including applying a composition to an area of human skin, the composition comprising a base and a plurality of abrasive particles, and manipulating the composition over the area of human skin with a handle-operated instrument.

Abstract: A dry composition for oral ingestion characterized by comprising as an active ingredient a gas-releasing substance which releases gas by soak with water, and further comprising a gel base in an amount sufficient for gel formation; a gel composition for oral ingestion formed by adding water or a liquid diluent to the dry compound when taking; and a mixed feed obtainable by mixing the gel composition with a feed, are disclosed.

Abstract: The present invention relates to antimicrobial carbon and to its use, especially for treating diseases and toxications of the gastrointestinal tracts, in particular diarrhoea.

Abstract: This invention generally relates to use of novel nanomaterials comprised of metals in anti-viral applications. Such nanomaterials, for example, can be produced using a high power, pulsed plasma process, which plasma process, optionally, can be performed on the metal with a precursor (i.e., a gaseous precursor, such as acetylene or methane) when forming the unagglomerated nanomaterials. In embodiments of the invention, the metal is nanosilver. Optionally, the nanomaterials may also comprise carbon, including in the form of carbyne.

Abstract: An oxidative stress inhibitor comprising a spherical activated carbon as an effective component is disclosed. The present invention is effective in the prevention or the treatment of a disease caused by oxidative stress, such as a kidney disease, a circulatory disease (for example, cardiovascular disease), a cancer, a diabetes, a cerebral stroke, or an arterial sclerosis.

Abstract: A method for making the microporous carbon with modified pore size distribution and advanced sorption behaviour. The carbon is derived from metal or metalloid carbides. The method employs the use of oxidant in reaction medium that during the carbide conversion into carbon widens small micropores, which otherwise would be hardly accessed by sorbing molecules or ions in practical applications. The microporous carbon obtained is free of impurities and possesses extremely narrow pore size distribution.

Abstract: A method for treating a gastrointestinal (GI) tract including providing a fiber/granule complex made of non-absorbable fibers having granules attached thereto, and ingesting the fiber/granule complex orally, wherein the fiber/granule complex treats materials in the GI tract as it passes through the GI tract, the fiber/granule complex not being substantially absorbed by the GI tract.

Abstract: The present invention relates to a biocidal composition, a method for its production and the use of the biocidal composition.

Abstract: The present invention provides a delivery system and method to deliver topically homeopathic amounts of at least one Homeopathic Complex. It further provides a Homeopathic Colored Pigment Product containing a coloring agent having a plurality of particles having at least one surface and a homeopathically effective amount of at least one Homeopathic Complex, wherein the at least one surface of particles in the plurality of particles of the coloring agent contains the at least one Homeopathic Complex. It also provides cosmetic formulations containing the Homeopathic Colored Pigment Product for normal skin, problem skin, aged skin, and skin damaged by the harmful rays of the sun.

Abstract: Methods, systems and formulations for normalizing and improving human body chemistry and the body's natural ability to heal itself.

Abstract: A micelle formable from at least one nanotube in a process of self-assembly, the nanotube comprising an amphophilic nanotube (2, 8, 14) made from one or more species selected from the group of carbon, silicon, a noble metal, silicon dioxide and titanium dioxide. A part of the nanotube (2, 8, 14) is functionalised and a surfactant molecule or emulsifying agent is attached to the functionalised part. The nanotube (2, 8, 14) may have magnetic properties. A therapeutic agent may be incorporated in the micelle. The micelle may be coated to form a capsule (24). The capsule (24) can be introduced to the human or animal body for treatment of tumors or targeted drug delivery when a magnetic field or near-IR radiation is applied.

Abstract: Described herein are pharmaceutically acceptable compositions comprising fullerene molecules dispersed in vesicles comprising phosphatidylcholine (PC) phospholipid molecules and non-PC phospholipid molecules suspended in aqueous solution. In preferred embodiments, the phospholipid molecules are substantially uniformly organized into vesicles composed of one or more lipid bilayers and the fullerene molecules are substantially uniformly distributed within the lipid bilayers of the vesicles. Methods of forming these fullerene containing liposomes are also described. Such fullerene containing liposomes provide carriers for delivery of fullerenes for cosmetic, therapeutic, and imaging applications among other uses.